Edition:
United Kingdom

John Miller

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

18 Jun 2018

After split from Actelion, Idorsia CEO plans to raise more cash in 2019

ALLSCHWIL, Switzerland Swiss biotech Idorsia , spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson , will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters.

01 Jun 2018

Novartis readies anti-sexism message for migraine drug

ZURICH With women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to adoption of its new medicine Aimovig. 

31 May 2018

Olympics, World Cup windfall add kick to Swiss economy

ZURICH Switzerland's economy grew robustly in the first quarter as a weaker franc supported exports and global sporting events helped fill the coffers of the Swiss-based International Olympic Committee (IOC) and soccer body FIFA.

31 May 2018

Sporting windfall gives boost to Swiss economy

ZURICH, May 31 Switzerland's economy grew robustly in the first quarter, as a weaker franc supported exports and global sporting events helped fill the coffers of the Swiss-based International Olympic Committee (IOC) and soccer body FIFA.

29 May 2018

Roche, chasing Merck, notches another lung cancer win

ZURICH Roche's bid to keep Merck's cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients' survival.

28 May 2018

Sulzer director's exit demonstrates extended reach of U.S. sanctions

ZURICH Russian oligarch Viktor Vekselberg's board representation at Swiss pump maker Sulzer dropped to three with the resignation of one of his allies on Monday in the latest instance of U.S. sanctions making waves in Europe's boardrooms.

16 May 2018

Novartis top lawyer exits over Trump attorney deal 'mistake'

ZURICH Novartis's top lawyer quit on Wednesday over a $1.2 million (890,419 pounds) contract he co-signed with U.S. President Donald Trump's personal attorney, a deal the Swiss drugmaker's ex-CEO also said was a mistake. | Video

16 May 2018

Novartis ex-CEO says regrets hiring, not firing Trump lawyer

ZURICH Ex-Novartis Chief Executive Joe Jimenez regrets rushing into a $100,000-per-month consulting contract with U.S. President Donald Trump's personal lawyer but said post-election uncertainty over the administration's healthcare ideas put pressure on the Swiss drugmaker to sign a deal quickly.

16 May 2018

Novartis ex-CEO says regrets hiring, not firing Trump lawyer

ZURICH Ex-Novartis Chief Executive Joe Jimenez regrets rushing into a $100,000-per-month (74,280 pounds) consulting contract with U.S. President Donald Trump's personal lawyer but said post-election uncertainty over the administration's healthcare ideas put pressure on the Swiss drugmaker to sign a deal quickly.

11 May 2018

Sika's deal with France's Saint-Gobain may make it a bid target

PARIS/ZURICH Swiss adhesives maker Sika has repelled a hostile takeover bid from Saint-Gobain in a $3.2 billion deal that gives the French company a minority stake but may make Sika a more attractive target for others.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,556.44 -70.96 -0.93%
DAX 12,511.91 -- --%
CAC 40 5,316.01 + 0.00 +0.00%
TR Europe 175.00 -1.42 -0.80%
GBP/USD 1.3262 +0.09%
GBP/EUR 1.1420 +0.03%
EUR/USD 1.1610 +0.08%
Gold 1,268.10 +0.90 +0.07%
Oil 66.46 +0.92 +1.40%
Corn 358.50 +1.50 +0.42%